secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001493152-25-019829
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies announces Australian patent acceptance for lung health platform
--------------------------------------------------------------------------------

- IP Australia accepted patent application AU 2019253111 for a flow cytometry-based platform to detect multiple lung diseases.
- The patent covers methods using fluorescent probes to identify cellular signatures of lung disease in sputum samples.
- Patent will be automatically issued in three months unless a third party files an opposition.
- Company now holds 18 awarded and 33 pending patents globally, including in the U.S., China, Japan, and Europe.
- The technology underpins CyPath® Lung, the company's noninvasive test for early-stage lung cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225019829/0001493152-25-019829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225019829/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer